Healthcare -
Biotechnology - NASDAQ - US
$ 1.68
-8.7 %
$ 125 M
Market Cap
-1.45
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Inhibikase Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 28.6 M |
| Operating Income | -28.6 M |
| Other Expenses | -1.07 M |
| Net Income | -27.5 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 0 | 0.3 | 0.1 | 3.1 | 0.7 | 1.1 | 4.0 | 2.1 | 1.0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 0 | 13.6 | 6.72 K | 11.4 | 0.9 | 2.6 | 3.6 | 1.8 | 0.8 |
| Gross Profit | 0 | (13.4) | 0.1 | (8.3) | (0.2) | (1.4) | 0.4 | 0.3 | 0.1 |
| OPERATING INCOME | |||||||||
| Operating Expenses | 28.6 | 6.7 | 18.1 | 14.8 | 2.8 | 5.7 | 2.1 | 2.5 | 0.7 |
| Selling, General and Administrative Expenses | 11.4 | 6.7 | 6.2 | 6.5 | 2.6 | 4.3 | 2.5 | 0.7 | 0.7 |
| Research and Development Expenses | 17.2 | 13.6 | 12.0 | 11.4 | 0.9 | 2.6 | 3.6 | 1.8 | 0.8 |
| Operating Income | (28.6) | (20.1) | (18.1) | (14.8) | (2.8) | (5.7) | (2.1) | (0.4) | (0.6) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | 0 | 0 | 74.5 K | 19.9 K | 29.4 K | 24.8 K | 30.3 K | 0 | 0 |
| Total Other Income | 1.1 | 1.1 | 74.5 K | 19.9 K | 29.4 K | 24.8 K | 30.3 K | 30.9 K | 15.4 K |
| Pre-Tax Income | (27.5) | (19.0) | (18.1) | (14.8) | (2.8) | (5.7) | (2.2) | (0.4) | (0.6) |
| NET INCOME | |||||||||
| Tax Provision | 0 | 0 | (0.1) | 19.9 K | 29.4 K | 24.8 K | (0.2) | (0.4) | 15.4 K |
| Net Income | (27.5) | (19.0) | (17.9) | (14.8) | (2.9) | (5.7) | (2.2) | (0.4) | (0.6) |
| EPS | 1.16 | 3.57 | 4.26 | 4.88 | 1.72 | 3.34 | 1.61 | 0.25 | 0.48 |